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S262 Poster Session IIfrom related (n5 265) vs. unrelated donors (n5 238), and 2) from
ABO matched (n5 292) vs. ABO mismatched donors (n5 211);
and 3) analyzed the impact of ABO incompatibility on nonmyeloa-
blative HCT outcomes. Related recipients required less platelet
and red blood cell (RBC) transfusions compared to unrelated recip-
ients (P\0.0001 for both), with comparable median numbers of
transfused units. Major/bidirectionally ABO-mismatched recipients
required more RBC transfusions than ABO-matched recipients
(P5 0.006). Rates of graft rejection/failure, grades II-IV acute
and chronic GVHD, 2-year relapse and 3-year survivals were com-
parable among ABO-matched, minor-mismatched, and major/bidi-
rectionally mismatched recipients (P5 0.93, 0.72, 0.57, 0.36 and
0.17, respectively). Times to disappearance of anti-donor IgG
and IgM isohemagglutinins among major/bidirectionally ABO-
mismatched recipients were affected by magnitude of pre-HCT
titers (P\0.001 for both) but not by GVHD (P5 0.71 and 0.78,
respectively) and donor type (P5 0.40 and 0.35, respectively). In
addition, we compared overall transfusion needs among patients re-
ceived myeloablative (n5 1353) vs. nonmyeloablative HCT. We
confirmed that myeloablative recipients required more platelet
and RBC transfusions than nonmyeloablative recipients (both
P\0.0001). Myeloablative patients given PBSC required less
platelet transfusions (P\0.0001) than those given marrow while
RBC transfusions did not differ significantly. Limiting the compar-
ison to PBSC recipients given the two different conditionings did
not change our findings. In conclusion, nonmyeloablative recipi-
ents required fewer platelet and RBC transfusions. Among them,
both unrelated and major/bidirectionally ABO-mismatched recipi-
ents required more RBC transfusions. However, ABO incompati-
bility did not affect any of the nonmyeloablative HCT outcomes.
Furthermore, anti-donor isohemagglutinin titers at the time of
transplantation predicted the tempo of titer disappearance after
transplantation.282
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Introduction: Hematopoietic stem cell transplant (HSCT) recipi-
ents have a high incidence of herpes zoster (HZ) following transplant
surgery. The primary objective of this study was to estimate the in-
cremental medical resource utilization (RU) and costs associated
with HZ in this population for the 21 days prior through 3 months
after diagnosis with HZ.
Methods:The MarketScan Research Databases from Thomson
Reuters (1999-2007) were assessed to determine the incremental
medical RU and cost due to HZ. Cases were selected if they
had an ICD-9-CM diagnostic code for HZ (053.x) following
evidence of receiving a hematopoietic stem cell transplant and
matched 1:1 via propensity scores to HSCT controls without
HZ. Differences in selected treatment and clinical characteristics
were assessed using t-tests for continuous variables and chi-
square tests for categorical variables. A two-part model (logistic
regression/negative binomial generalized estimating equations)
was selected for multivariate analysis of incremental medical
RU and costs.
Results: Of the 204 HSCT case recipients identified, 21.1%
(n5 43) were hospitalized with HZ as the principle diagnosis
(0 for controls), 10.8% (n5 22) were diagnosed with ophthalmic
HZ, (0 for controls) and 15.7% (n5 32) with neurological im-
pairment due to HZ (0 for controls). There were no claims for
disseminated HZ or for the administration of IV acyclovir within
7 days of HZ diagnosis. There was no significant difference in
opportunistic infections between cases and controls (47 versus
43, p5 0.533). HSCT recipients with HZ had significantly
more medical RU in all categories (inpatient admissions, averagelength of stay, emergency room visits, number of outpatient
visits, number of other outpatient services, and out patient pre-
scriptions) compared to controls (p\0.01). HSCT recipients
with HZ also had significant incremental medical costs due to
HZ (See Table 1).
Conclusions: Herpes zoster has a significant impact on the health,
medical service use and medical costs for HSCT recipients. Future
advances for the treatment or prevention of HZ in HSCT recipients
should be given strong consideration to help alleviate this medical
burden.
Table 1. Herpes Zoster related Medical Costs for HSCT
Recipients
N Observed Adjusted*HSCTwith HZ 204 $14,424 $10,452
HSCTwithout HZ (controls) 204 $6,215 $5,661
Incremental Cost $8,209 $4,791
Lower 95% C.I. $4,558
Upper 95% C.I. $5,042*p\0.0001 for the adjusted incremental cost.283
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In many countries tuberculosis is an important public health prob-
lem and early BCG vaccine is used to prevent severe forms of the dis-
ease. In these same countries, the diagnosis of severe combined
immunodeficiency (SCID) is usually delayed and children may
have disseminated BCG infection at the time they are referred to he-
matopoietic stem cell transplantation (HSCT). Our objective is to
describe the experience transplanting young children with SCID
and tuberculosis in two Brazilian institutions.
Methods: retrospective chart review.
Results:A total of 23 childrenwith SCIDhad allogeneic transplants.
Three patients had received BCG vaccine and were treated with at
least three drugs to prevent dissemination.Nine patients had dissem-
inated Mycobacterium bovis infection, described in the table. Me-
dian age at transplant was 14 months (5-39), 6 were male. Patients
had matched sibling donor transplants (N5 2), matched father (1)
or haploidentical mother (1), 5/6 unrelated cord blood (4) or marrow
(1). The vaccine scar usually produced a very prominent skin lesion
that ulcerated and drained after engraftment. Patients also presented
with enlarged axillary and retroperitoneal lymphnodes and hepatic/
spleen lesions that becamemore visible on ultrasound, CT orMRI at
the time of hematological recovery. All patients were treated with at
least 5 drugs (streptomycin, isoniazid, rifampin, ethambutol, cipro-
floxacin, azithromycin or clarithromycin) for 1-2 years, until com-
plete resolution of all signs of the disease and complete
immunological recovery. Six patients are alive 0.5-11 years post
transplant.
Conclusion: BCG-infection is not a contraindication for
HSCT in SCID patients. Axillary adenopathy, hepatic and
spleen nodules are common at presentation. All clinical find-
ings worsen with engraftment and may slowly resolve after im-
munological recovery and prolonged therapy with multiple
antibiotics.
Patients with disseminated BCG infections
Initials,
gender
Age at BMT
(months) Donor
Preparative regimen/ GVHD
prophylaxis Tuberculosis Other complications Outcome
GBS, male 10 Unrelated 5/6 Cord
Blood
Busulfan, Cyclofosfamide, ATG/
Cyclosporine-Steroids
Vaccine wound, lung infiltrates,
finger, eritema nodosum,
osteomyelitis
Venoclusive disease, acute
GVHD, Mycobacterium
kansassi osteomyelitis
11 years post transplant,
complete immunological
recovery
BSF, male 15 Unrelated 5/6 Marrow None/ T-cell depletion-
Cyclosporine
Vaccine wound, pneumonia,
subcutaneous nodules,
generalized adenopathy, gut
infection
Acute respiratory distress on
mechanical ventilation, EBV
gut infection with prolonged
parenteral nutrition (for 18
months)
11 years post transplant
doing well, without
infections.
ASR, male 24 Matched Sibling
Marrow
None Vaccine wound Acute GVHD 5 years post transplant alive
and well with complete
donor chimerism and
immunological recovery
ECS, female 14 Matched Related
Marrow (Father)
None Axillary LN, retroperitoneal LN,
vaccine wound, spleen, liver,
lung
Acute GVHD, multiple
bacteremias, osteomyelitis,
fever (40 C) daily for six
months
4 years post transplant with
full immunological
recovery, still has
calcified lesions in the
liver and spleen
GFC, male 39 Unrelated 5/6 Cord
Blood
Busulfan-Fludarabine/
Cyclosporine-Steroids
Mycobacterium bovis and
M.kansassi disseminated
infections
Acute and extensive chronic
GVHD. Severe autoimmune
hemolytic anemia. Skin
infection (Microsporidium).
Candidemia
Died D1 469 with mixed
chimerism due to severe
infections and
malnutrition
LLC, female 14 Unrelated 5/6 Cord
Blood
Busulfan/ Cyclosporine Axillary LN, vaccine wound Acute GVHD, RSV pneumonia,
CMV pneumonia),
Candidiasis, bloodstream
infections; nephrotic
syndrome
1 year post transplant with
mixed chimerism and
severe lymphopenia
after Campath for
autoimmune hemolytic
anemia
GAC, male 12 Unrelated 5/6 Cord
Blood
Busulfan-Fludarabine/
Cyclosporine-MMF
Axillary and retroperitoneal LN,
liver, spleen
Candidiasis, multiple hepatic
nodules, CMV-cholecistitis,
RSV
5 months post transplant
tapering CsA with
recurrent infectious
problems despite
complete donor
chimerism
TVVM, male 7 Matched sibling donor None Vaccine wound, pneumonia.
Ulcer in the arm after
enfraftment
Engraftment syndrome followed
by graft rejection
Died on D1 98 due to
Fusarium sp infection
AO, female 5 Haploidentical Mother None/CD34 selection and T-cell
depletion
Pneumonia and septic shock - Died few days after
transplant with no
engraftment
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THE MSKCC EXPERIENCE WITH OUTPATIENT INTERMITTENT DOSING
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FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT
Goldberg, J.D., Barker, J.N., Castro-Malaspina, H.R., Jakubowski, A.A.,
Abboud, M., Tucker, A., Ford, R., Perales, M.-A. Memorial Sloan-Ket-
tering Cancer Center, New York, NY
Introduction: Although antifungal prophylaxis is standard treat-
ment following alloHSCT, and data support the use of mold-active
agents in the first 100 days or in the setting of GVHD, a number of
patients do not tolerate commonly indicated azoles.Micafungin is an
echinocandin with activity against Candida and Aspergillus species.
PK studies and murine models suggest intermittent dosing of mica-
fungin is efficacious and safe. An alternate day regimen ofmicafungin
for the treatment of esophageal candidiasis (300 mg QOD) was
shown to have similar efficacy to standard daily dosing of micafungin
(150 mg) or caspofungin (50 mg). Based on these data, we developed
a regimen of intermittent dosing of micafungin for antifungal pro-
phylaxis post alloHSCT.
Methods: Patients were followed between May 2007, when we ini-
tiated intermittent dosing of micafungin, and June 2009. Fourteen
patients (age range 23-63, mean 43) received intermittent dosing
of micafungin, either at home (n5 7) or in the infusion center(n5 7). Micafungin was given for prophylaxis in 11 patients (5
with GVHD) and in combination therapy with voriconazole
(n5 2) or liposomal amphotericin B (n5 1) in patients with pre-
sumed fungal pneumonia. Thirteen patients received micafungin
300 mg 3x/week. One patient initiated prophylaxis at 300 mg 2x/
week. The infusion frequency was decreased to 2x/week for 3 pa-
tients with GVHD as prednisone was tapered. Patients were fol-
lowed clinically and with routine imaging for development or
progression of fungal infection.
Results:At the conclusion of observation, 11 patients receiving drug
for prophylaxis (n5 8) or treatment of presumed invasive fungal in-
fection (n5 3) had completed treatment. The remaining patients
continued prophylaxis twice weekly. Themedian treatment duration
was 61 days (range 17 to .528d). A possible breakthrough fungal
pneumonia was observed after 17 days of prophylactic micafungin
3x/week in a patient on systemic steroids for GVHD and with a his-
tory of presumed fungal pneumonia pre-HSCT. No serious adverse
events were noted with the increased dose of micafungin.
Discussion: These preliminary data indicate that intermittent dos-
ing of micafungin post alloHSCT appears to be safe and effective
and may provide an outpatient alternative for patients unable to tol-
erate azoles or those requiring combination therapy. Also, our data
provides support for a study to evaluate this new dosing schedule
in alloHSCT patients and other high-risk populations.
